Processa Pharmaceuticals, Inc.
$2.15
-0.0050 (-0.23%)
Join the Processa Pharmaceuticals, Inc. Investor Community
Get the latest news and company updates delivered straight to your inbox. Subscribe for free to stay ahead of the story and follow Processa Pharmaceuticals, Inc. as new developments unfold.
Clinical Trial Pipeline Stages
| Drug Name | Stage |
|---|---|
| NGC- Gemcitabine (PCS3117)DetailsPancreatic cancer, Cancer, Non-small cell lung carcinoma, Gall bladder cancer | Phase 2/3 |
| NGC- Capecitabine (PCS6422)DetailsCancer, Colorectal cancer , Solid tumor/s, Pancreatic cancer, Breast cancer | Phase 2 |
| PCS12852DetailsOpioid induced constipation, Post-op GI Dysfunction | Phase 2a |
| PCS499DetailsUlcerative Necrobiosis Lipoidica | Failed |
Sign Up For PCSA Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Processa Pharmaceuticals, Inc (PCSA) is a client of RedChip Companies Inc. PCSA agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in April 2025, and 50,000 shares of PCSA Rule 144 stock for 6 months of RedChip investor awareness services. RedChip intends to and will, if possible, sell all of its shares immediately upon removal of the restriction, and you may be buying as RedChip is selling.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.